I-Corps: MedsForAll - I-Corps Winter Cohort Customer Discovery Training Program

I-Corps：MedsForAll - I-Corps 冬季队列客户发现培训计划

• 批准号: 1911374
• 负责人: Andreas Stergachis
• 金额: $ 5万
• 依托单位: University of Washington
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1911374&HistoricalAwards=false
• 关键词: Corps; MedsForAll; Winter; Cohort; Customer

The broader impact/commercial potential of this I-Corps Project is to conduct customer discovery interviews to identify initial customers that can support a universal medication autoinjector platform technology that can democratize accessibility to medications. A direct ampule autoinjector system can leverage the existing global medical infrastructure of the ampule-based medication cartridge while expanding accessibility of medications. From a cost effectiveness and cost minimization perspective, an equally safe and efficacious drug delivery platform technology will require complex advancements in the scientific and technological understanding of injection systems that can deliver a consistent dose of medication free of particulate contamination, air bubbles, and is also user intuitive with little to no technical training. The potential societal impact of this technology can save many lives since having wider access to this technology can prevent death or disability that can arise if patients undergoing medical situations are not treated quickly. This platform technology can also protect emergency responders, civilians and military personnel exposed to biological or chemical threats. The potential commercial impact of the project can disrupt the multi-billion-dollar health care market, democratize health care access, while being capable of expanding into global markets.This I-Corps project will further the development and commercialization of direct ampule-based autoinjector technology through customer discovery. Technical results of the feasibility of the technology under development have been proven through the development of a proof of concept that can consistently deliver a volume of medication. These results have been further refined to the publication of a patent undergoing review. The NSF sponsored customer discovery program will help the team develop the framework for conducting customer discovery interviews in a structured format while incorporating interview responses and data into a commercialization strategy for product to market execution. The intellectual merits of the proposed activity will help the team identify how current needs are being addressed regarding the administration of medications while more importantly identifying if those needs are truly met and or if there are other needs that can be met which currently are not met. The I-Corps customer discovery training program can help the project team identify stakeholders, key opinion leaders and develop a customer segmentation profile that can more accurately identify actual customers and payers in the health care medical device ecosystem while seeking avenues for collaboration in the healthcare industry.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛影响/商业潜力是进行客户发现访谈，以确定可以支持通用药物自动注射器平台技术的初始客户，该技术可以使药物的可及性民主化。 直接安瓿自动注射器系统可以利用现有的基于安瓿的药物药筒的全球医疗基础设施，同时扩大药物的可及性。 从成本效益和成本最小化的角度来看，同样安全和有效的药物输送平台技术将需要对注射系统的科学和技术理解的复杂进步，该注射系统可以输送一致剂量的药物，而没有颗粒污染、气泡，并且还具有用户直观性，几乎没有技术培训。 这项技术的潜在社会影响可以挽救许多人的生命，因为更广泛地获得这项技术可以防止如果病人在医疗情况下没有得到迅速治疗而可能出现的死亡或残疾。 该平台技术还可以保护紧急救援人员、平民和军事人员免受生物或化学威胁。 该项目的潜在商业影响可能会扰乱数十亿美元的医疗保健市场，使医疗保健服务大众化，同时能够扩展到全球市场。该I-Corps项目将通过客户发现进一步开发和商业化直接安瓿自动注射器技术。 正在开发的技术的可行性的技术结果已经通过开发一个概念验证得到证明，该概念验证可以持续提供一定量的药物。 这些结果已被进一步完善，以发表正在审查的专利。 NSF赞助的客户发现计划将帮助团队开发以结构化格式进行客户发现访谈的框架，同时将访谈响应和数据纳入产品上市执行的商业化战略。 拟议活动的知识价值将有助于团队确定如何解决当前的药物管理需求，同时更重要的是确定这些需求是否真正得到满足，或者是否有其他目前未得到满足的需求可以满足。 I-Corps客户发现培训计划可以帮助项目团队识别利益相关者，该奖项反映了NSF的法定使命，并通过使用基金会的知识产权进行评估，被认为值得支持。优点和更广泛的影响审查标准。